Top Story

VIDEO: Australia achieves high HCV therapy uptake among injection drug users

April 22, 2019
Meeting News

NGM313 shows ‘acute and significant’ reductions in NASH markers

April 22, 2019
VIENNA — A single dose of NGM313 demonstrated improvements in multiple noninvasive markers of nonalcoholic steatohepatitis, according to a presentation at the…
FDA News

FDA approves generic Narcan nasal spray

April 22, 2019
The FDA recently approved the first generic nasal spray of the opioid overdose antidote Narcan for use in a community setting without medical training, according to a…

Most injection drug users in 8 US cities have been infected with HCV

April 22, 2019
More than 55% of people who inject drugs, or PWID, in eight United States cities were found to have been infected with hepatitis C virus, including almost half of young…
Meeting NewsVideo

VIDEO: Givosiran may ‘transform’ lives of patients with acute hepatic porphyria

April 20, 2019
VIENNA — In this exclusive video from the 2019 International Liver Congress, Akin Akinc, PhD, of Alnylam Pharmaceuticals, discusses results of a study in which…
More Headlines »

Cirrhosis and Hepatic Encephalopathy – Managing Their Consequences and Complications

This activity is supported by an educational grant from Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC.

Cirrhosis, or advanced fibrosis of the liver, can lead to serious health sequelae or death. However, substantial…
More »
GI Bookshelf

Question 28: I Have A Patient With Biliary-Type Pain, But No Other Evidence Of Bile Duct Disease (Normal Diameter Duct On Ultrasound, Normal Liver Function Tests). How Should Such A Patient Be Managed?

From Curbside Consultation in Endoscopy: 49 Clinical Questions, Second Edition
More »
Resource Centers
International Liver Congress

International Liver Congress

Meeting News

VIDEO: Transparency improves patient care, builds just culture

April 17, 2019
More »
Current Issues Current Issues
View the Current Issue
HCV Next